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CD73, ecto-5󸀠-nucleotidase, is the key enzyme catalyzing the conversion of extracellular AMP to adenosine that controls vascular
permeability and immunosuppression. Also prostatic acid phosphatase (PAP) possesses ecto-5󸀠-nucleotidase/AMPase activity and
is present in leukocytes. However, its role related to immune system is unknown. Therefore, we analyzed enzymatic activities and
leukocyte subtypes of CD73 and PAP knockouts and generated CD73/PAP double knockout mice to elucidate the contribution of
CD73 and PAP to immunological parameters. Enzymatic assays confirmed the ability of recombinant human PAP to hydrolyze
[3H]AMP, although at much lower rate than human CD73. Nevertheless, 5󸀠-nucleotidase/AMPase activity in splenocytes and
lymphocytes from PAP−/− mice tended to be lower than in wild-type controls, suggesting potential contribution of PAP, along
with CD73, into lymphoid AMP metabolism ex vivo. Single knockouts had decreased number of CD4+/CD25+/FoxP
3
+ regulatory
T cells in thymus and CD73/PAP double knockouts exhibited reduced percentages of CD4+ cells in spleen, regulatory T cells in
lymph nodes and thymus, and CD4+ and CD8+ cells in blood. These findings suggest that PAP has a synergistic role together with
CD73 in the immune system by contributing to the balance of leukocyte subpopulations and especially to the number of regulatory
T cells in lymph nodes and thymus.
1. Introduction
Balance between extracellular ATP, ADP, AMP, and adeno-
sine controls the inflammatory status of the microenviron-
ment, because ATP is proinflammatory while adenosine is
highly anti-inflammatory. CD73 ectonucleotidase is a key
enzyme in the purinergic signaling cascade as it dephos-
phorylates AMP and produces adenosine. Both endothelial
cells and certain subsets of leukocytes express CD73. On
endothelium [1–4] CD73-dependent adenosine production
controls vascular permeability as clearly demonstrated by
leaky vasculature and aggravated inflammations in CD73
deficient mice [5–8]. Regulatory T cells (Tregs) express CD73
and exert their immunosuppressive effects via adenosine.
On the other hand, adenosine promotes Treg expansion and
triggers A
2A adenosine receptor on effector T cells inducing
NF-kB-mediated suppression of cytokine production and
other anti-inflammatory effects [9, 10].
Human prostate expresses high amounts of PAP and
the levels of the enzyme activity in serum has been con-
nected to prostate cancer already decades ago [11], and in
the recent years PAP has become the target for prostate
cancer immunotherapy [12]. Indeed, there are two iso-
forms of prostatic acid phosphatase, a secretory (sPAP) and
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a type 1 transmembrane (TMPAP) isoform, which are splice
variants encoded by the same gene (ACPP) [13]. PAP presents
ecto-5󸀠-nucleotidase activity, and subsequent studies have
unambiguously demonstrated its wide expression beyond
the prostate including leukocytes [14], and the TMPAP
isoform has been found in various tissues, including spleen,
thymus, and neurons [13, 15]. Besides substrates such as
𝛽-glycerophosphate, lysophosphatidic acid, and phospho-
amino acids, PAP can also catalyze AMP [16] and, in fact,
PAP-mediated adenosine formation has been shown to be
an important regulator of pain by inhibiting nociceptive
neurotransmission [17–19]. Thus, the studies regarding PAP
have concentrated on its function in the prostate and the
neural system and, unlike CD73, its role in the immune
system has remained unknown. In this work, we analyzed
the nucleotidase activities of purified hPAP in comparison
to recombinant CD73 in vitro and, further, ex vivo by using
lymphoid cell suspensions isolated fromwild type, CD73 and
PAP knockout, andCD73/PAP double knockoutmice, as well
as mouse lymph nodes and human tonsils cryosections as
enzyme sources.Moreover, we show the consequences of PAP
deficiency alone and combined with the absence of CD73 to
the composition of immune cells in main lymphoid organs.
To the best of our knowledge, this is the first demonstration
of a role for PAP in the immune system.
2. Materials and Methods
2.1. Mice. 𝑃𝑎𝑝−/− (mPAP KO) and𝑁𝑡5𝑒−/− (CD73 KO) were
created by targeted gene disruption as previously described
[20, 21]. Mice were backcrossed to C57BL/6J mice for >10
generations. dKO (mPAP KO/CD73 KO) mice were gener-
ated by breeding backcrossed 𝑁𝑡5𝑒−/− and 𝑃𝑎𝑝−/− mice and
the double mutant mice were selected by PCR-based geno-
typing.They were analyzed alongside age-matched C57BL/6J
wild type mice as controls. Two- to 4-month-old mice were
used. Mice were raised under a 12 : 12 light : dark cycle and
used during the light phase. The mice were maintained in
a specific pathogen-free stage at Central Animal Laboratory
at the University of Turku, complying with international
guidelines on the care and use of laboratory animals and
performed in compliance with the 3Rs principle. All animal
experiments were approved by the Finnish Animal Ethics
Committee, project license number 3791/04.10.03/2011.
2.2. Purification of Human CD73 and PAP. Recombinant
human CD73 was purified from transfected CHO
cells. The harvest was purified using immobilized
N6-(6-amino)hexyl-AMP (Jena Bioscience Gmbh, Jena,
Germany). The bound rhCD73 was eluted using 0.25M
AMP in 50mM Tris-HCl, 0.1M NaCl, and pH 7.4. After the
purification, the buffer was changed to 20mM Tris-HCl, pH
8.0, using AmiconUltra 30 device and the final concentration
of the CD73 was measured using specific in-house ELISA.
hPAP was purified from human seminal plasma as
described previously [22, 23]. Enzyme specific activity for
the dephosphorylation of p-nitrophenylphosphate at pH 4.8
(50mM Na citrate buffer) was 5500𝜇mol/min∗mg.
2.3. Cell Isolation, Flow Cytometric Analyses, and Immuno-
histochemistry. Single cell suspensions were prepared from
minced pieces of peripheral lymph nodes (pooled axial and
inguinal nodes), thymus, and spleen by mechanical teasing
through ametalmeshwork and bonemarrow cells by flushing
the femurs. Blood was collected by cardiac puncture. Ery-
throcytes were removed from spleen and blood by hypotonic
lysis. Leukocyte phenotyping was done using mAbs against
CD4 (clone RM4-5, Alexa Fluor 647 conjugated), CD8
(clone 53-6.7, PerCP-Cy5.5 conjugated), and anti-B220 (clone
RA3-6B2, Pacific blue conjugated), all obtained from BD
Biosciences. Regulatory T cells were identified using mouse
regulatory T cell staining kit (eBioscience; CD4-FITC, CD25-
allophycocyanin, and FoxP3-PE). Cells were analyzed using
LSRII using BDFACS-Diva software. Representative dot blots
and histograms were made with FlowJo software. Frozen
sections of thymuses were also stained for CD8, CD4, and
CD25.
2.4.Thin-Layer Chromatographic (TLC)Analysis of Enzymatic
Activities. Purinergic activities of isolated single cells from
bone marrow, spleen, and peripheral lymph nodes were
determined by using [2,8-3H]ATP, [2,8-3H]ADP (Perkin
Elmer), [2-3H]AMP (Quotient Bioresearch, GE Health-
care, Rushden, UK), and [2-3H]adenosine (Amersham, Lit-
tle Chalfont, UK) as described previously [24]. Briefly,
the single cell suspensions (5–10 × 104 cells) were incu-
bated for 45–60min at 37∘C in a final volume of 80 𝜇L
RPMI-1640 in neutral pH supplemented with 4mmol/L 𝛽-
glycerophosphate and the following tracer substrates: 500𝜇M
[3H]ATP (ATPase), 500 𝜇M [3H]ADP (ADPase), 300 𝜇M
[3H]AMP (ecto-5󸀠-nucleotidase), 300 𝜇M [3H]adenosine
(adenosine deaminase), and 400𝜇M [3H]AMP plus 600 𝜇M
𝛾-phosphate-donating ATP (adenylate kinase). Likewise,
AMP-hydrolyzing activity of purified human enzymes was
determined by incubating PAP (1 𝜇g of protein) or CD73
(0.5 ng) with 40 𝜇M [3H]AMP in the absence and pres-
ence of 𝛽-glycerophosphate (4mmol/L) or selective ecto-5󸀠-
nucleotidase/CD73 inhibitor 𝛼,𝛽-methylene-ADP (AMPCP;
5 𝜇M).Mixture aliquots were applied onto AlugramG/UV
254
sheets (Macherey-Nagel) and 3H-labeled substrates and their
metabolites were separated by TLC and quantified by scintil-
lation 𝛽-counting.
2.5. Enzyme Histochemistry. Localization of ecto-5󸀠-
nucleotidase/AMPase and other nucleotidase activities was
determined in murine lymph node and also human tonsil
cryosections by using a modification of the lead nitrate
[Pb(NO
3
)
2
] method, as described previously [25, 26]. Tissue
sections were also stained with hematoxylin and eosin.
Slides were mounted with Aquatex (Merck) and images were
acquired using an Olympus BX60 microscope.
2.6. Statistical Analyses. The results are presented as mean ±
SEM, unless otherwise stated. Statistical analyses were done
using two-sided Student’s 𝑡-test and values of 𝑃 < 0.05 were
considered significant.
Mediators of Inflammation 3
3. Results and Discussion
3.1. Activity of CD73 Dominates over PAP in AMP Hydrolysis
Both In Vitro and In Vivo. As PAP has been demonstrated
to contribute, along with a predominant role of CD73, to
the conversion of extracellular AMP into adenosine [16,
17], we first compared the activities of purified hPAP and
purified CD73. Measurement of hPAP activity revealed
efficient hydrolysis of artificial substrate pNPP by the purified
enzyme (Figure 1(a)) and further demonstrated its ability
to metabolize [3H]AMP (Figure 1(b)), with highest catalytic
activities being detected at acidic pH. Interestingly, AMP-
hydrolyzing capability of hPAP was ∼400- and ∼50-fold
less in comparison with purified CD73 when assayed at
pH 7.2 and 5.5, respectively, and, in addition, it was not
inhibited by selective ecto-5󸀠-nucleotidase inhibitor AMPCP
(Figure 1). Noteworthy, PAP could also potentially hydrolyze
𝛽-glycerophosphate as an alternative phosphorylated sub-
strate [16]. However, no differences in the rates of [3H]AMP
hydrolysis by purified hPAP or hCD73 were detected in our
TLC assays performed in the absence and presence of 4mM
𝛽-glycerophosphate (data not shown).
To further evaluate the potential role of PAP in lymphoid
nucleotide homeostasis, we measured the activities of ecto-
5󸀠-nucleotidase (Figure 2(a)) and other related purinergic
enzymes, ATPase (Figure 2(b)), ADPase (Figure 2(c)), and
adenylate kinase (Figure 2(d)), in lymphocytes isolated from
spleen and bone marrow of PAP knockout and wild type
mice. No statistical differences were found in these activi-
ties, although there was a tendency towards reduced ecto-
5󸀠-nucleotidase activity in the spleen of the PAP knock-
out mice. Next, we concentrated on lymphocytes isolated
from peripheral lymph nodes, which drain the periphery
and are the primary sites for immune response against
antigens arriving from the periphery via afferent lymphat-
ics, and analyzed the enzymatic activities in wild type,
CD73, PAP, and CD73/PAP double knockouts. The dou-
ble knockouts generated for this work did not show any
obvious phenotype, when housed in specific pathogen-free
conditions.
As expected, practically no AMPase activity was detected
in the lymphocytes isolated from CD73 knockout mice, thus
confirming that lymphoid ecto-5󸀠-nucleotidase/CD73 indeed
represents the major enzyme responsible for conversion of
extracellular AMP into adenosine (Figure 3(a)). Nonetheless,
as in the case of spleen studies (see Figure 2(a)), a clear
trend for diminished [3H]AMP hydrolysis was observed
in PAP−/− lymphocytes (Figure 3(a)). These data suggest
that PAP may contribute, along with CD73, to lymphoid
AMP metabolism, presumably in certain synergistic fashion.
Consistent with our previous observations [27], we also
found significantly increased ATPase and ADPase activities
in lymphocytes from CD73 deficient animals, with the latter
nucleotidase activity remaining significantly upregulated also
in CD73/PAP double knockout mice. No significant shifts in
other purine-converting enzymes, adenosine deaminase and
adenylate kinase, were detected among the studied genotypes
(Figure 3).
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Figure 1: Nucleotidase activities of purified human PAP and
recombinant human CD73. (a) The activities of hPAP and hCD73
were determined spectrophotometrically at neutral or acidic pH
by using artificial substrate p-nitrophenylphosphate (pNPP). ND:
nondetectable. Radio-TLC analysis of nucleotidase activities was
also performed by incubating purified hPAP (b) and hCD73 (c) with
40 𝜇M [3H]AMP at different pH without and with 5 𝜇MAMPCP, as
indicated. Enzymatic activities are expressed as 𝜇moles of pNPP or
[3H]AMP hydrolyzed per hour by onemilligram of enzyme protein.
∗𝑃 < 0.05.
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Figure 2: PAP deficient mice do not have significant alterations in extracellular nucleotide metabolism. The activities of ecto-5󸀠-
nucleotidase/AMPase (a), ATPase (b), ADPase (c), and adenylate kinase (d) were determined radiochemically in bone marrow and spleen
leukocytes isolated from wild type and PAP knockout mice (mean ± SEM; 𝑛 = 3–5).
3.2. PAP and CD73 Are Differently Expressed in Mouse
and Human Lymphoid Tissues and Contribute to Nucleotide
Metabolism. The distribution of different nucleotidases in
the lymphoid tissues was then evaluated in situ by a
lead precipitation method. Short-time incubation of mouse
lymph node and human tonsil cryosections with different
nucleotide substrates revealed the presence of high AMPase
and especially ATPase activities (Figure 4). The employment
of TMP as a substrate and increasing the incubation time
also allowed us to detect relatively moderate but clearly
visible staining, which was specifically restricted to the
subcapsular area of mouse lymph nodes, the epithelial layer
of human tonsils, and also individual lymphoid cells scattered
throughout the lymphoid tissues (Figure 4). Strikingly, the
most intense TMPase staining was observed at acidic pH,
suggesting the predominant contribution of PAP enzyme
to the measured nucleotidase activity. Noteworthy, it has
been proposed recently that selective expression of tissue-
nonspecific alkaline phosphatase and another pH-dependent
enzyme tartrate-resistant acid phosphatase (TRAP) in corre-
sponding alkaline and acidic lacunas of bone might function
as specific pH sensors directionally regulating nucleotide
receptor-mediated osteoclast function and bone resorption
[28]. It is also pertinent to mention that, under certain
circumstances, like ischemia, intracellular pH is decreased to
∼6.4, accompanied by marked inhibition of 5󸀠-nucleotidase
activity and changes in purine homeostasis in the heart [29].
It may be reasonably speculated that different localization of
CD73 and PAP and their inverse pH dependence provide
efficient means for tuned regulation of purine homeostasis
in lymphoid tissues during inflammation, hypoxia, and other
(patho)physiological states. Further studies are required to
validate this hypothesis.
3.3. PAP Deficiency Has Only Minor Effect on Lymphocyte
Populations. As there is no reliable antibody to analyze PAP
expression at the protein level in mouse, we were mining
the ImmGen consortium data bank that contains detailed
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Figure 3: Purine-converting activities in CD73 and PAP deficient mice. The activities of ecto-5󸀠-nucleotidase/AMPase (a), ATPase (b),
ADPase (c), adenylate kinase (d), and adenosine deaminase (e) were determined by TLC in lymph node lymphocytes from wild type mice
(𝑛 = 14), CD73 single (𝑛 = 7), PAP single (𝑛 = 9), and CD73/PAP double knockouts (𝑛 = 7). Enzymatic activities were expressed as
nanomoles of 3H-substrate metabolized per hour by 106 cells. ∗∗𝑃 ≤ 0.01, ∗∗∗𝑃 ≤ 0.001.
analyses of different murine leukocyte and endothelial cell
populations in respect to their gene expression profiles. PAP
is expressedmainly in subsets of 𝛾𝛿T cells and invariant natu-
ral killer T cells in thymus and both in CD4 and CD8 positive
T cells in secondary lymphoid organs although generally in
lower levels than CD73. A simplified comparison to CD73
expression is shown in Table 1. PAP deficiency alone did not
change B cell, CD8, or CD4 populations in mice (Figures
5(a)–5(d)). The only statistically significant difference was
seen in CD8+ cells in the blood, although in percentage-wise
the increase is most likely biologically meaningless.The same
held true when the lymphocyte populations were analyzed
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Figure 4: Distribution of nucleotidase activities in mouse lymph nodes and human tonsils. Enzyme histochemical staining was performed
by incubating tissue sections at different pH for the indicated time without (Blank) and with different nucleotide substrates. Tissue sections
were also stained with hematoxylin and eosin (H&E). The capsules are indicated by dashed lines, the arrows point at some positive scattered
cells, GC: germinal center, SS: subcapsular sinus, and E: epithelium. Original magnification: ×100. Scale bar: 200 𝜇m.
in blood and bone marrow of 8-month-old PAP mice (data
not shown). We chose this time point as PAP knockout mice
develop nonmetastatic prostate carcinoma at an old age [30].
Theknockout prostates at this age containedmoreB cells than
wild type prostates (6.6 ± 0.2% versus 1.4 ± 0.9%, 𝑃 = 0.004).
Also salivary glands containmore immune cells in thesemale
mice, when they are young, but the difference disappears with
aging [31]. The practically nonexisting alterations of major
immune cell subpopulations in absence of PAP suggest that
PAP does not seem to have any marked role in the immune
system or its absence is compensated by CD73. Likewise,
the changes in CD73 knockout mice were minor (Figures
5(a)–5(d)). Fewer B cells and slightly increased number of
regulatory T cells were detected in peripheral lymph nodes.
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Figure 5: Synergistic effect of PAP and CD73 deficiency on the leukocyte subpopulations. Lymphocyte phenotypes in blood (a), spleen (b),
lymph nodes (c), and thymus (d) of wild type mice (𝑛 = 7), CD73 single (𝑛 = 3), PAP single (𝑛 = 6), and CD73/PAP double knockouts
(𝑛 = 4) (thymus: 𝑛 = 3 for all genotypes) were analyzed using flow cytometry. (e) Regulatory T cells in lymph nodes. Examples of the FACS
analyses of regulatory T cells in wild type and CD73/PAP KOmice are shown. In the left panels the gating strategy is shown and in the middle
panels percentages of CD4+/CD25+ cells are indicated. Intensities of FoxP3 stainings of CD4+/CD25+ cells are shown as histograms in the
right panels. Logarithmic fluorescence is on 𝑥-axis and the number of cells on 𝑦-axis. (f) Combined results of regulatory T cell analyses of
different organs are shown as indicated. ∗𝑃 ≤ 0.05, ∗∗𝑃 ≤ 0.01, and ∗∗∗𝑃 ≤ 0.001.
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Figure 6:Thymuses of CD73/PAP double knockouts show comparable morphology and cell distribution to wild type mice. (a) Hematoxylin
and eosin stainings of wild type and CD73/PAP knockout thymuses. (b) Immunofluorescence stainings of wild type and CD73/PAP knockout
thymuses using anti-CD4 (green) and anti-CD25 (red) antibodies.
3.4. CD73 and PAP Together Regulate the Number of CD4 and
CD8Cells in Blood andNumber of Regulatory TCells in Lymph
Nodes and Thymus. In single knockouts, the number of
regulatory T cells was significantly decreased in thymus and
in the double knockouts both in PLN and thymus (Figures
5(e) and 5(f)). Still the intensity of FoxP3 expression, amarker
for regulatory T cells, was at the same level in both double
knockouts and wild type mice (Figure 5(e)). Thus, we may
conclude that in thymus both CD73 and PAP contribute to
number of regulatory T cells alone, but absence of both is
needed to have an effect in PLN.
Although adenosine produced by CD73 on regulatory T
cells propagates generation of more regulatory T cells via A
2A
adenosine receptor [32], the number of regulatory T cells is
very low and the main adenosine may come from peripheral
lymph node stromal cells such as from endothelial cells. The
stromal cells were not included in our enzymatic analyses
showing nearly complete absence of ecto-5󸀠-nucleotidase
activity on isolated lymph node lymphocytes in CD73 KO
mice.
Our finding of normal levels of regulatory T cells in
organs other than in thymus, which had decreased number
of regulatory T cells, and in lymph nodes, which had slightly
increased number of regulatory T cells, is in agreement with
the observation of Ehrentraut et al. [33], who did not find
differences in the number of regulatory T cells between wild
type and CD73 deficient mice in the lungs.This demonstrates
that expression of CD73 overall is not needed for generation
of regulatory T cells as such, although it is fundamental for
the immunosuppressive function of these cells [9, 33].
The double knockout mice also have significantly lower
percentages of CD8+ (32% reduction, 𝑃 < 0.0001) and
CD4+ cells (51% reduction, 𝑃 < 0.006) in their blood and
reduced number of CD4+ cells in the spleen (Figures 5(a) and
5(b)) further suggesting the synergistic effects of these two
enzymes in controlling the lymphocyte pools.
As thymus is the central organ in T cell development,
we also analyzed thymic morphology and T cell subtypes
of CD73, PAP, and double knockouts and compared them
to those of wild type mice. The double knockout mice had
normal thymic morphology (Figure 6(a)) and tissue location
of different cell types was comparable between the genotypes.
Double stainings of CD4 and CD25 are shown as examples in
Figure 6(b).
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Table 1: Expression profiles of CD73 and PAP at the mRNA level in
different lymphoid tissues∗.
CD73 (Nt5e) PAP (Acpp)
Thymus
𝛾𝛿 T cells∗∗ 𝛾𝛿 T cells∗∗
CD4 single positive iNKT precursors∗∗
Double negative thymocytes
CD8 single positive, mature
iNKT∗∗∗ precursors∗∗
Lymph nodes
CD4 memory CD8 naı¨ve
CD8 na¨ıve
CD8 memory
Treg
Blood endothelial cells
Spleen
Germinal center B cells CD4 na¨ıve
Memory B cells CD4 memory
𝛾𝛿 T cells∗∗ 𝛾𝛿 T cells∗∗
CD4 na¨ıve CD8 na¨ıve
CD4 memory CD8 memory
CD8 na¨ıve iNKT cells
CD8 memory
Treg
iNKT cells
NK cells∗∗
∗The data has been collected from the Immunological Genome Project
(http://www.immgen.org/databrowser). The cell types with an expression
value (EV) >120 for a given gene are listed (95% confidence of positive
expression).
∗∗Only in selected subpopulations.
∗∗∗iNKT = invariant natural killer T cells.
Lymph nodes, spleen, and blood represent anatomically
and functionally different environments for leukocytes pro-
viding unique cellular networks and extracellularmilieu.This
can also be realized by the differences in the expression of PAP
and CD73 (Table 1). Therefore, our results showing organ-
specific changes in lymphocyte subpopulations of double
knockouts are understandable and emphasize the fact that,
for example, in lymphnodes and spleen the factors promoting
activation and differentiation of regulatory T cells are at least
partially different and in spleen not markedly regulated by
CD73 and PAP, although both enzymes are present in these
organs. Regulatory T cells are produced in thymus and from
there they disperse throughout the body to various organs in
the hematolymphoid system or differentiated in the periph-
ery. Regulatory T cells are heterogeneous regarding their phe-
notype, function, and epigenetic status and also the homing-
associated molecules on regulatory T cells vary [34, 35]. This
allows them to preferentially migrate to different organs such
as peripheral lymph nodes, gut-associated lymphatic tissues,
spleen, or nonlymphoid organs depending on the pattern of
homing-receptors on their surface [35]. For example, CXCL12
highly expressed in bonemarrow and splenic red pulp attracts
regulatory T cells, while CCL25 recruits them to the small
intestine.Thus, the regulatory T cells in different organs have
phenotypically unique characteristics.
4. Conclusions
Generation andmaintenance of the balance between different
leukocyte subpopulations is a key element for proper func-
tioning of the immune system in health and diseases. Anti-
inflammatory adenosine produced by the AMPase activity of
CD73 is central in immunosuppression. Although adenosine
is important propagating regulatory T cells, lack of CD73 has
surprisingly little effect on the number of regulatory T cells.
This is the first report demonstrating the distribution of PAP
in various mouse and human lymphoid tissues and its con-
tribution, in conjunction with CD73, to the lymphoid purine
homeostasis and the balance of leukocyte subpopulations in
various organs. However, alone absence of PAP does not have
any significant effect outside the thymus, but, combined to the
deficiency with CD73, the consequences become significant.
Further work is needed to elucidate the exact mechanism of
the mode of action of PAP in the immune system.
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